Pharmaceuticals, Biotechnology and Life Sciences
WEST CHESTER, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology…
Investigators concluded that the encouraging oncologic outcomes coupled with a favorable safety profile warrant further evaluation in a randomized trial23…
CHMP opinion now expected in 1Q 2025 No Major Objections outstanding; continue to expect Germany launch in 2Q 2025 PITTSBURGH,…
Company to host conference call on Wednesday, December 11, 2024 at 7am ETCAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) —…
January 13-16, 2025, San Francisco, CAIRVINE, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) — Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics…
Demonstrated durable hematologic response across all patient subgroups, regardless of baseline transfusion status and concomitant JAK inhibitor therapyPhase 2 study…
SHANGHAI, Dec. 08, 2024 (GLOBE NEWSWIRE) — Shanghai Zelixir Biotechnology Co., Ltd. (“Zelixir”) today announced the official operation of its…
– ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia – –…
100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4…
In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response…